Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company specializing in innovative treatments for hypertension and related conditions, has announced its plans to report its financial results for the fourth quarter and full year ending December 31, 2025. The announcement is set for March 12, 2026, after the market closes, with the conference call scheduled for 4:30 p.m. ET the same day. Interested parties can join the call by dialing in via a domestic line at 1-877-704-4453 or an international line at 1-201-389-0920, using the Conference ID: 13758574. Additionally, a live webcast of the conference will be available on the Investor Relations section of the Mineralys website, allowing stakeholders an opportunity to engage directly with the company's latest insights.

Mineralys Therapeutics is based in Radnor, Pennsylvania, and was established by Catalys Pacific, focusing on addressing hypertension and related comorbidities including chronic kidney disease (CKD) and obstructive sleep apnea (OSA). Their lead candidate, lorundrostat, is a proprietary oral medication functioning as a highly selective aldosterone synthase inhibitor, aimed at mitigating the effects of aldosterone dysregulation on various health conditions.

The reporting of the financial results is particularly significant as it will shed light on the company’s performance and strategic developments over the past year. Stakeholders, analysts, and potential investors are expected to closely monitor this event, seeking insights into Mineralys' growth trajectory, commercialization efforts, and future plans within the competitive biopharmaceutical landscape. For more details, visit their website or connect with their investor relations team.

As Mineralys Therapeutics prepares to announce its fourth quarter and full year 2025 financial results, investors should closely monitor the upcoming conference call on March 12, 2026. This event will provide crucial insights into the company’s financial health and strategic directions, particularly regarding its lead candidate, lorundrostat, aimed at addressing hypertension and its related comorbidities, including chronic kidney disease (CKD) and obstructive sleep apnea (OSA).

Analysts should pay particular attention to key metrics such as revenue growth, R&D expenditures, and any updates surrounding clinical trial outcomes for lorundrostat. Given the increasing focus on hypertension as a major public health issue, the reception of lorundrostat in the market could significantly drive the company's valuation post-announcement.

Investors should also scrutinize the company’s guidance for the upcoming year, especially in terms of expected milestones like regulatory approvals or partnership announcements. Based on historical performance and industry trends, clarity on these fronts could bolster investor confidence.

With the biopharmaceutical sector's inherent volatility, understanding regulatory impacts and market dynamics is critical. Any positive news regarding lorundrostat’s efficacy or safety profile could catalyze a substantial uptick in share price, while disappointing results may lead to downward pressure.

Moreover, maintaining a diversified portfolio is advisable, particularly if indications suggest high risk associated with single-product dependence. The broader healthcare landscape continues to evolve, highlighting the importance of monitoring competitor developments and potential market entry of alternatives in the hypertension treatment space.

As such, investors should approach the March 12 call with a strategic mindset, prepared to adapt to whichever direction Mineralys Therapeutics takes based on the financial results and management's commentary.